@article{199eba26125f4080941bab0c5140c2f6,
title = "Home-based exergaming to treat gait and balance disorders in patients with Parkinson's disease: A phase II randomized controlled trial",
abstract = "Background: Exergaming has been proposed to improve gait and balance disorders in Parkinson's disease (PD) patients. We aimed to assess the efficacy of a home-based, tailored, exergaming training system designed for PD patients with dopa-resistant gait and/or balance disorders in a controlled randomized trial. Methods: We recruited PD patients with dopa-resistant gait and/or balance disorders. Patients were randomly assigned (1:1 ratio) to receive 18 training sessions at home by playing a tailored exergame with full-body movements using a motion capture system (Active group), or by playing the same game with the computer's keyboard (Control group). The primary endpoint was the between-group difference in the Stand-Walk-Sit Test (SWST) duration change after training. Secondary outcomes included parkinsonian clinical scales, gait recordings, and safety. Results: Fifty PD patients were enrolled and randomized. After training, no significant difference in SWST change was found between groups (mean change SWST duration [SD] -3.71 [18.06] s after Active versus -0.71 [3.41] s after Control training, p = 0.61). Some 32% of patients in the Active and 8% in the Control group were considered responders to the training program (e.g., SWST duration change =2 s, p = 0.03). The clinical severity of gait and balance disorders also significantly decreased after Active training, with a between-group difference in favor of the Active training (p = 0.0082). Home-based training induced no serious adverse events. Conclusions: Home-based training using a tailored exergame can be performed safely by PD patients and could improve gait and balance disorders. Future research is needed to investigate the potential of exergaming.",
keywords = "exergaming, falls, gait disorders, Parkinson's disease, rehabilitation",
author = "Dijana Nuic and Sjors van de Weijer and Saoussen Cherif and Anna Skrzatek and Eline Zeeboer and Claire Olivier and Corvol, {Jean Christophe} and Pierre Foulon and Pastor, {J{\'e}nica Z.} and Gregoire Mercier and Brian Lau and Bloem, {Bastiaan R.} and De Vries, {Nienke M.} and Welter, {Marie Laure}",
note = "Funding Information: The research was supported by the France Parkinson Association, Eurostars programme (Grant EUROSTARS E! 10634), and Agence Nationale de la Recherche (Grant ANR LabCom No. ANR-13-LAB1-0003-01/ANR1 18-LCCO-0004-01). Funding Information: D.N., S.v.d.W., S.C., A.S., E.Z., C.O., J.-C.C., J.Z.P., G.M., B.L., B.R.B., N.M.d.V., and M.-L.W. declare they have no conflict of interest relative to the research. D.N., A.S., S.v.d.W., C.O., J.Z.P., G.M., S.C., and E.Z. have no conflict of interest to declare. B.L. received research grants from the Brain Institute Foundation and Agence Nationale de la Recherche outside of this work. P.F. is employed by Genious Healthcare France which has no property rights on the data. J.-C.C. received research grants from the Paris Brain Institute, France Parkinson, and Agence Nationale de la Recherche outside of this work; fees for advisory boards for Servier, Biophytis, Biogen, UCB, Prevail Therapeutics, and Alzprotect outside of this work. B.R.B. serves as the Co-Editor in Chief for the , serves on the editorial board of and , has received fees from serving on the scientific advisory board for UCB, Kyowa Kirin, Zambon, and the Critical Path Institute (paid to the Institute), has received fees for speaking at conferences from AbbVie, Biogen, UCB, Zambon, Roche, GE Healthcare, Oruen, Novartis, and Bial (paid to the Institute), and has received research support from the Netherlands Organisation for Health Research and Development, The Michael J. Fox Foundation, UCB, the Stichting Parkinson Fonds, Hersenstichting Nederland, de Stichting Woelse Waard, Stichting Alkemade-Keuls, de Maag Lever Darm Stichting, Parkinson NL, Davis Phinney Foundation, the Parkinson's Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, Nothing Impossible, and the Parkinson Vereniging outside the submitted work. N.M.d.V. received research grants from the Netherlands Organisation for Health Research and Development outside of this work. M.L.W. received research grants from the Paris Brain Institute, Agence Nationale de la Recherche, The Michael J. Fox Foundation, and Boston Scientific; and personal fees from Boston Scientific and Medtronic outside of this work. Journal of Parkinson's Disease Practical Neurology Digital Biomarkers Publisher Copyright: {\textcopyright} 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.",
year = "2024",
month = jan,
doi = "10.1111/ene.16055",
language = "English",
volume = "31",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley",
number = "1",
}